CDT EQUITY INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
CDT EQUITY INC. (CDT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $1.50 million for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-08.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-09-08
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $1.50M S-1 · filed 2026-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |